Prognostic role of pancreatic metastases from renal cell carcinoma: Results from an Italian center

Clinical Genitourinary Cancer

Volumn 11, Issue 4, 2013, Pages 484-488

  Grassi, Paolo ^a   Verzoni, Elena ^a   Mariani, Luigi ^a   De Braud, Filippo ^a   Coppa, Jorgelina ^a   Mazzaferro, Vincenzo ^a   Procopio, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

mTOR inhibitors; Pancreas; Renal cell carcinoma; Targeted therapy; Tyrosine kinase inhibitors

Indexed keywords

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER PROGNOSIS; CANCER SURGERY; FEMALE; FOLLOW UP; HUMAN; ITALY; KIDNEY CARCINOMA; KIDNEY METASTASIS; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS METASTASIS; THYROID METASTASIS;

MTOR INHIBITORS; PANCREAS; RENAL CELL CARCINOMA; TARGETED THERAPY; TYROSINE KINASE INHIBITORS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; COHORT STUDIES; FEMALE; HUMANS; ITALY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL;

EID: 84888009026     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2013.04.022     Document Type: Article

References (21)

1. J. Ferlay, D.M. Parkin, and E. Steliarova-Foucher Estimates of cancer incidence and mortality in Europe in 2008 Eur J Cancer 46 2010 765 781
2. A.A. Renshaw Subclassification of renal cell neoplasms: an update for the practising pathologist Histopathology 41 2002 283 300
3. T.M. Mekhail, R.M. Abou-Jawde, and G. Boumerhi Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma J Clin Oncol 23 2005 832 841
4. R. Ballarin, M. Spaggiari, and N. Cautero Pancreatic metastases from renal cell carcinoma: the state of the art World J Gastroenterol 17 2011 4747 4756
5. R.J. Motzer, N.H. Bander, and D.M. Nanus Renal-cell carcinoma N Engl J Med 335 1996 865 875
6. N.K. Janzen, H.L. Kim, and R.A. Figlin Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease Urol Clin North Am 30 2003 843 852
7. D.S. Sandock, A.D. Seftel, and M.I. Resnick A new protocol for the followup of renal cell carcinoma based on pathological stage J Urol 154 1995 28 31
8. N.V. Adsay, A. Andea, and O. Basturk Secondary tumors of the pancreas: an analysis of a surgical and autopsy database and review of the literature Virchows Arch 444 2004 527 535
9. J.P. Faure, J.J. Tuech, and J.P. Richer Pancreatic metastasis of renal cell carcinoma: presentation, treatment and survival J Urol 165 2001 20 22
10. L.D. Thompson, and C.S. Heffess Renal cell carcinoma to the pancreas in surgical pathology material Cancer 89 2000 1076 1088
11. C.H. Law, A.C. Wei, and S.S. Hanna Pancreatic resection for metastatic renal cell carcinoma: presentation, treatment, and outcome Ann Surg Oncol 10 2003 922 926
12. F. Sellner, N. Tykalsky, and M. De Santis Solitary and multiple isolated metastases of clear cell renal carcinoma to the pancreas: an indication for pancreatic surgery Ann Surg Oncol 13 2006 75 85
13. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
14. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
15. C.N. Sternberg, I.D. Davis, and J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
16. B.I. Rini, B. Escudier, and P. Tomczack Comparative effectiveness of abitini versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase III trial Lancet 378 2011 1931 1939
17. G. Hudes, M. Carducci, and P. Tomczack Temsirolimus, interferon alfa or both for advanced renal-cell carcinoma N Eng J Med 356 2007 2271 2281
18. R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
19. B. Escudier, A. Pluzanska, and P. Koralewski Bevacizumab plus interferon alfa-2a for treatment of metastaic renal cell carcinoma: a randomised, double blind phase III trial Lancet 370 2007 2103 2111
20. R.J. Motzer, M. Mazumdar, and J. Bacik Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol 17 1999 2530 2540
21. P.J. Elson, R.S. Witte, and D.L. Trump Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma Cancer Res 48 1988 7310 7313